These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35272914)

  • 1. In Vitro Apixaban Removal By CytoSorb Whole Blood Adsorber: An Experimental Study.
    Røed-Undlien H; Schultz NH; Lunnan A; Husebråten IM; Wollmann BM; Molden E; Bjørnstad JL
    J Cardiothorac Vasc Anesth; 2022 Jun; 36(6):1636-1644. PubMed ID: 35272914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
    Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Rupp A; Blumenstock G; Zuern CS; Ziemann U; Poli S
    J Am Heart Assoc; 2018 Oct; 7(19):e009807. PubMed ID: 30371316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.
    Dinkelaar J; Patiwael S; Harenberg J; Leyte A; Brinkman HJ
    Clin Chem Lab Med; 2014 Nov; 52(11):1615-23. PubMed ID: 24902009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of direct oral anticoagulants on thrombin generation on Ceveron TGA.
    Pfrepper C; Behrendt LC; Bönigk H; Siegemund T; Metze M; Franke D; Petros S; Siegemund A
    Int J Lab Hematol; 2022 Feb; 44(1):193-201. PubMed ID: 34585540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement.
    Helin TA; Virtanen L; Manninen M; Leskinen J; Leppilahti J; Joutsi-Korhonen L; Lassila R
    J Thromb Thrombolysis; 2017 May; 43(4):562-569. PubMed ID: 28315166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers.
    Cheung YW; Barco S; Hutten BA; Meijers JC; Middeldorp S; Coppens M
    J Thromb Haemost; 2015 Oct; 13(10):1799-805. PubMed ID: 26270625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage.
    Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
    J Thromb Haemost; 2015 Dec; 13(12):2220-6. PubMed ID: 26447393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.
    Escolar G; Fernandez-Gallego V; Arellano-Rodrigo E; Roquer J; Reverter JC; Sanz VV; Molina P; Lopez-Vilchez I; Diaz-Ricart M; Galan AM
    PLoS One; 2013; 8(11):e78696. PubMed ID: 24244342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How the direct oral anticoagulant apixaban affects thrombin generation parameters.
    Tripodi A; Padovan L; Veena C; Scalambrino E; Testa S; Peyvandi F
    Thromb Res; 2015 Jun; 135(6):1186-90. PubMed ID: 25895845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
    Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
    Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracorporeal hemoadsorption therapy as a potential therapeutic option for rapid removal of Apixaban in high risk-surgical patients: a case report.
    Dalmastri V; Angelini A; Minerva V; Ballarini M; Grammatico F; Todeschini P; Pizzini AM; Silingardi M; La Manna G
    J Med Case Rep; 2023 Jul; 17(1):283. PubMed ID: 37415195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme.
    Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jacquemin M; Jochmans K; Mullier F; Wijns W; China B; Vernelen K; Soumali MR
    Int J Lab Hematol; 2017 Aug; 39(4):402-408. PubMed ID: 28304137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation.
    Pujadas-Mestres L; Lopez-Vilchez I; Arellano-Rodrigo E; Reverter JC; Lopez-Farre A; Diaz-Ricart M; Badimon JJ; Escolar G
    PLoS One; 2017; 12(2):e0171486. PubMed ID: 28192448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
    Schenk B; Würtinger P; Streif W; Sturm W; Fries D; Bachler M
    Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide.
    Douxfils J; Chatelain C; Chatelain B; Dogné JM; Mullier F
    Thromb Haemost; 2013 Aug; 110(2):283-94. PubMed ID: 23765180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
    Song Y; Wang Z; Perlstein I; Wang J; LaCreta F; Frost RJA; Frost C
    J Thromb Haemost; 2017 Nov; 15(11):2125-2137. PubMed ID: 28846831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.
    Gouin-Thibault I; Flaujac C; Delavenne X; Quenet S; Horellou MH; Laporte S; Siguret V; Lecompte T
    Thromb Haemost; 2014 Feb; 111(2):240-8. PubMed ID: 24172843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CytoSorb haemoadsorption for removal of apixaban-A proof-of-concept pilot case for a randomized controlled trial.
    Buonocore M; Rex S; Degezelle K; Meyns B
    J Clin Pharm Ther; 2022 Dec; 47(12):2373-2375. PubMed ID: 36351749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban.
    Tripodi A; Chantarangkul V; Padovan L; Clerici M; Scalambrino E; Peyvandi F
    J Thromb Thrombolysis; 2020 Apr; 49(3):413-419. PubMed ID: 31728842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.
    Martin AC; Le Bonniec B; Fischer AM; Marchand-Leroux C; Gaussem P; Samama CM; Godier A
    Int J Cardiol; 2013 Oct; 168(4):4228-33. PubMed ID: 23928345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.